Published in Hepatitis Weekly, December 30th, 2002
The test can discriminate between active or carrier status. It should allow for rapid identification of people who would benefit from either vaccination or treatment say researchers who evaluated the test, which was developed by Binax, Inc., of Portland, Maine.
Researchers at Ghent University and Hospital in Belgium used the HBsAg/eAg test on 942 serum samples. "The clinical sensitivity of the HBsAg/eAg test was 99.75% and 96.37% for HBsAg and HBeAg, respectively," F....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.